DIM
QTTB icon

DLK Investment Management’s Q32 Bio QTTB Stock Holding History

DLK Investment Management’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,333
Closed -$20.5K – 95
2025
Q3 		$20.5K Hold
10,333
– – 0.01% 88
2025
Q2 		$15.4K Buy
+10,333
New +$17.6K 0.01% 87
2024
Q1 		– Sell
-3,333
Closed -$36.5K – 112
2023
Q4 		$36.5K Buy
+3,333
New +$48.7K 0.02% 94

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DLK Investment Management's QTTB Position: Q4 2025 in Review

DLK Investment Management sold out of Q32 Bio (QTTB) in Q4 2025, closing a stake of 10,333 shares — an estimated $20.5K sold.

DLK Investment Management first reported a position in QTTB in Q4 2023 and held it in 3 quarters. The position peaked at $36.5K in Q4 2023. 52 funds tracked by Wall St. Rank hold QTTB as of Q4 2025.

  • DLK Investment Management reported no remaining Q32 Bio position as of Q4 2025 after selling out during the quarter.
  • DLK Investment Management sold 10,333 Q32 Bio shares in Q4 2025, an estimated $20.5K.
  • DLK Investment Management first reported a position in Q32 Bio in Q4 2023 and held it in 3 quarters.
  • DLK Investment Management's Q32 Bio position peaked at $36.5K in Q4 2023.
  • 52 funds tracked by Wall St. Rank held Q32 Bio as of Q4 2025.

Based on DLK Investment Management's 13F filing for Q4 2025, filed 14 Jan 2026.